BridgeBio Pharma, Inc.
(NASDAQ : BBIO)

( )
BBIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -11.87%310.610.0%$5071.29m
BNTXBioNTech SE -4.91%334.480.0%$1509.60m
NVAXNovavax, Inc. -7.66%192.6578.2%$1000.81m
AMGNAmgen, Inc. 0.97%200.801.4%$596.73m
GILDGilead Sciences, Inc. 0.00%68.931.0%$502.66m
REGNRegeneron Pharmaceuticals, Inc. -0.93%630.592.7%$480.14m
VRTXVertex Pharmaceuticals, Inc. 9.66%205.001.9%$469.49m
LGVNLongeveron Inc. -22.20%20.430.0%$404.67m
ILMNIllumina, Inc. -2.10%357.663.3%$316.55m
SNSSSunesis Pharmaceuticals, Inc. -10.85%4.110.7%$287.30m
BIIBBiogen, Inc. -2.65%229.501.8%$286.58m
OCGNOcugen, Inc. -4.89%6.030.0%$251.60m
INCYIncyte Corp. -4.08%64.962.4%$161.20m
EXASEXACT Sciences Corp. -5.96%80.2818.0%$157.41m
SGENSeagen Inc. -1.09%158.255.8%$147.19m

Company Profile

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.